Goldman Sachs Group Inc Harmony Biosciences Holdings, Inc. Transaction History

Goldman Sachs Group Inc

$596 Billion
Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 344,766 shares of HRMY stock, worth $12.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

344,766

Previous 344,766 -0.0%

Holding current value

$12.1 Million

Previous $11.4 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	SELL	$32.18 - $40.46 $4.84 Million - $6.08 Million	-150,282 Reduced 30.36%	344,766 $11.4 Million
Q4 2024 Feb 11, 2025	BUY	$31.86 - $41.49 $5.96 Million - $7.76 Million	187,035 Added 60.72%	495,048 $17 Million
Q3 2024 Nov 14, 2024	SELL	$30.0 - $39.95 $4.42 Million - $5.89 Million	-147,351 Reduced 32.36%	308,013 $12.3 Million
Q2 2024 Aug 13, 2024	BUY	$28.81 - $33.01 $7.04 Million - $8.07 Million	244,410 Added 115.86%	455,364 $13.7 Million
Q1 2024 May 15, 2024	SELL	$29.93 - $35.06 $1.8 Million - $2.11 Million	-60,146 Reduced 22.19%	210,954 $7.08 Million
Q4 2023 Feb 13, 2024	BUY	$19.2 - $33.78 $1.33 Million - $2.34 Million	69,142 Added 34.24%	271,100 $8.76 Million
Q3 2023 May 14, 2024	SELL	$31.89 - $39.03 $2.2 Million - $2.7 Million	-69,142 Reduced 25.5%	201,958 $6.62 Million
Q3 2023 Nov 14, 2023	SELL	$31.89 - $39.03 $3.67 Million - $4.49 Million	-115,045 Reduced 36.29%	201,958 $6.62 Million
Q2 2023 May 14, 2024	SELL	$30.5 - $37.4 $345,595 - $423,779	-11,331 Reduced 3.45%	317,003 $11.2 Million
Q2 2023 Aug 14, 2023	SELL	$30.5 - $37.4 $345,595 - $423,779	-11,331 Reduced 3.45%	317,003 $11.2 Million
Q1 2023 May 14, 2024	BUY	$30.8 - $53.92 $6.75 Million - $11.8 Million	219,310 Added 201.16%	328,334 $10.7 Million
Q1 2023 May 11, 2023	BUY	$30.8 - $53.92 $6.75 Million - $11.8 Million	219,310 Added 201.16%	328,334 $10.7 Million
Q4 2022 May 14, 2024	SELL	$45.4 - $60.91 $2.57 Million - $3.45 Million	-56,587 Reduced 34.17%	109,024 $6.01 Million
Q4 2022 Feb 13, 2023	SELL	$45.4 - $60.91 $2.57 Million - $3.45 Million	-56,587 Reduced 34.17%	109,024 $6.01 Million
Q3 2022 May 14, 2024	BUY	$42.06 - $55.45 $4.09 Million - $5.4 Million	97,334 Added 142.56%	165,611 $7.34 Million
Q3 2022 Nov 10, 2022	BUY	$42.06 - $55.45 $4.09 Million - $5.4 Million	97,334 Added 142.56%	165,611 $7.33 Million
Q2 2022 May 14, 2024	SELL	$33.54 - $52.15 $6.8 Million - $10.6 Million	-202,823 Reduced 74.81%	68,277 $3.33 Million
Q2 2022 Aug 15, 2022	BUY	$33.54 - $52.15 $154,887 - $240,828	4,618 Added 7.25%	68,277 $3.33 Million
Q1 2022 May 16, 2022	BUY	$33.14 - $51.13 $555,194 - $856,580	16,753 Added 35.72%	63,659 $3.1 Million
Q4 2021 Feb 14, 2022	SELL	$34.09 - $43.91 $259,424 - $334,155	-7,610 Reduced 13.96%	46,906 $2 Million
Q3 2021 Nov 10, 2021	BUY	$25.68 - $38.61 $1.4 Million - $2.1 Million	54,516 New	54,516 $2.09 Million

Others Institutions Holding HRMY

# of Institutions

278

Shares Held

44.8M

Call Options Held

130K

Put Options Held

46.5K

View Full List

About Harmony Biosciences Holdings, Inc.

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $2.07B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

More about HRMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Harmony Biosciences Holdings, Inc. Transaction History